NAD+: The Coenzyme Behind the Aging Conversation

The short version

NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is a small molecule every living cell already makes and depends on. It works two ways: as a redox carrier, shuttling electrons through the reactions that turn food into usable energy, and as a substrate, meaning enzymes like sirtuins and PARPs consume it to run DNA repair and gene-regulation processes.

The reason NAD+ leads this desk is that its levels measurably decline with age, and restoring them — usually via precursor molecules like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) rather than NAD+ itself — has become one of the most active threads in aging research. Human trials have consistently shown these precursors do raise blood NAD+. Whether that translates into a measurable, clinically meaningful anti-aging benefit is a separate and still-open question, one a 2025 review answered cautiously ^[6].

This page covers what has actually been measured in humans, not what supplement marketing claims — and it does not recommend a dose.

What it is

NAD+ is a dinucleotide — two nucleotides joined by bridging phosphate groups — built from nicotinamide mononucleotide and adenosine monophosphate. It exists in an oxidized form (NAD+) and a reduced form (NADH), and the ratio between the two is itself a marker of cellular metabolic state. Molecular formula C21H27N7O14P2. Because NAD+ itself is broken down before it can cross into cells intact, oral NAD+ supplements are widely considered a poor delivery strategy; the two precursors studied in human trials, NMN and NR, are absorbed and converted to NAD+ inside cells, and IV or injectable NAD+ delivers it directly into the bloodstream rather than through digestion.

How it works

NAD+ sits at the center of cellular energy metabolism, shuttling electrons through glycolysis, the TCA cycle, and oxidative phosphorylation to generate ATP. Separately, it is consumed as a substrate by three families of signaling enzymes: sirtuins (SIRT1 through SIRT7), which regulate gene expression and metabolism; PARPs (chiefly PARP1), which repair damaged DNA; and CD38/CD157, cell-surface enzymes that break NAD+ down and whose activity rises with age and inflammation ^[9][11]. Because sirtuins, PARPs, and CD38 all draw from the same NAD+ pool, a rising CD38 burden with age is thought to out-compete the other two for a shrinking supply — the mechanistic rationale for why restoring NAD+ levels is studied as an anti-aging strategy. In mice, deleting CD38 preserves NAD+ levels and mitochondrial function into old age, supporting this model ^[11].

What the research shows

Human clinical evidence, synthesized. A 2025 narrative review of the human trial evidence on NAD+ precursor supplementation in aging concluded that human trials have shown limited efficacy, that age-related NAD+ decline has been consistently observed only in a limited number of human studies, and that tissue-specific NAD+ dynamics remain understudied — calling for more human trials rather than continued extrapolation from rodent data ^[6].

NMN, walking distance. In a multicenter, double-blind randomized trial, oral NMN (300-900 mg/day for 60 days) dose-dependently raised blood NAD+ in middle-aged adults and improved walking distance and quality-of-life scores versus placebo, with 600 mg/day identified as the apparent optimal dose and no safety issues at any dose tested ^[7].

NMN, insulin sensitivity. In prediabetic, postmenopausal women, 10 weeks of oral NMN (250 mg/day) significantly improved muscle insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp, though body composition and HbA1c did not change ^[8].

NR, dose-response. In healthy overweight adults, NR at 100-1000 mg/day for 8 weeks dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively, with no flushing and no significant difference in adverse events from placebo at any dose ^[10].

Mechanism: CD38. CD38 is the principal NAD+-consuming enzyme whose activity rises with age; CD38-knockout mice are protected from age-related NAD+ decline and retain better mitochondrial function ^[11].

Heart failure model. In human myocardium and a mouse model of heart failure with preserved ejection fraction, restoring oxidized NAD+ reactivated a ketogenic enzyme (HMGCS2), increased fatty-acid oxidation, and rescued cardiac function — a mechanistic link between NAD+ metabolism and cardiac aging ^[12].

Reported effects, cautions & safety

Because NAD+ is a coenzyme rather than a peptide most people inject and feel directly, structured personal-experience reports are thinner here than for the other three compounds on this desk. What follows instead is drawn from the published trial-safety data and the documented controversies around NAD+ supplementation and IV therapy — no anecdotal reports are asserted here because none rise to a level worth repeating.

The clinical-trial safety record for oral NMN and NR is reassuring within its scope: neither the 60-day NMN trial nor the 8-week NR dose-escalation trial found significant excess adverse events versus placebo at any dose tested, and NR did not raise LDL cholesterol or disrupt one-carbon metabolism ^[7][10]. That said, the same 2025 review that synthesizes the human trial evidence is explicit that efficacy data remain limited and that tissue-specific NAD+ dynamics are still sparsely characterized — raising blood NAD+ is well demonstrated, but translating that into a hard clinical outcome is not yet established ^[6].

Two cautions apply specifically to IV or injectable NAD+, which is a different delivery route from the oral trials above and rests on far less controlled human evidence: infusions run too quickly are reported to cause chest or abdominal discomfort, flushing, and nausea, and the FDA has issued a Class I recall of a compounded NAD+ injection over elevated bacterial endotoxin — a product-quality risk tied to compounding, not to NAD+ itself. A further theoretical caution, raised in the oncology literature, is that boosting NAD+ could in principle support the metabolism of an existing cancer, since NAD+ also fuels proliferating cells; this is mechanism-based reasoning, not a demonstrated human harm.

Where it fits in healthspan and cellular-aging research

NAD+ is the mechanistic hub this desk organizes around: it is the coenzyme that BPC-157's repair signaling, semaglutide's metabolic protection, and Thymosin Alpha-1's immune restoration all ultimately draw energy and DNA-repair capacity from, even though none of the four have been studied together directly. Of the four, NAD+ has the most human dosing trials but arguably the least settled translation from biomarker change (raised blood NAD+) to a clinical outcome anyone would call anti-aging. See the comparison page for how its evidence maturity stacks up against the other three.